alexa In-silico Interaction Studies of Quinazoline Derivative
ISSN: 0974-276X

Journal of Proteomics & Bioinformatics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

In-silico Interaction Studies of Quinazoline Derivatives for their Inhibitory Action on Both Wild and Mutant EGFRs

Kaushik S. Hatti, V. Chandregowda, G.Venkateswara Rao, Anil Kush, G.Chandrasekara Reddy*

Vittal Mallya Scientific Research Foundation, P.B.No 406, K.R.Road, Bangalore-560004, INDIA

*Corresponding Author:
Dr. G.Chandrasekara Reddy
Vittal Mallya Scientific Research Foundation
P.B.No 406, K.R.Road, Bangalore-560004, INDIA
E-mail: [email protected]

Received Date: February 03, 2009; Accepted Date: March 11, 2009; Published Date: March 12, 2009

Citation: Kaushik SH, Chandregowda V, Venkateswara RG, Anil K, Chandrasekara RG (2009) In-silico Interaction Studies of Quinazoline Derivatives for their Inhibitory Action on Both Wild and Mutant EGFRs. J Proteomics Bioinform 2: 126-130. doi:10.4172/jpb.1000069

Copyright: © 2009 Kaushik SH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Epidermal growth factor receptor (EGFR) family has gained importance as a target for cancer therapy. However, somatic mutations in the tyrosine kinase domain of EGFR alter its sensitivity to anti-EGFR tyrosine kinase (TK) drugs like gefitinib (IressaTM). Docking studies of a few newly synthesized 6, 7-dialkoxy-4-anilinoquinazoline derivatives which showed EGFR-TK inhibitory activity were conducted. It has been found that the docking energies of these novel quniazolines are comparable with the IC50 values against A431 and MCF-7 tumor cell lines. Though the compounds with benzoxazole (1 & 2) and imidazole side chain (4) exhibited low binding energy to wild-type, but compound 3 had the lowest binding energy to its mutants as well (T790M, L858R and double-mutant). Compounds 1, 2, 4 and gefitinib showed affinity only for selective EGFR variants.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version